home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410p.zip
/
M94A3062.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
45 lines
Document 3062
DOCN M94A3062
TI Course of CD8+CD38+ lymphocyte subset during continuous AZT-ddC
combination therapy in 25 HIV infected individuals.
DT 9412
AU Holmgren C; Knechten H; Praxiszentrum, Aachen, Germany.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):162 (abstract no. PB0073). Unique
Identifier : AIDSLINE ICA10/94369513
AB INTRODUCTION: The CD8+CD38+ lymphocyte subset is a marker for
progression of HIV infection but there have been few reports about the
course of this subset during antiretroviral combination therapy. Thus,
development of this subset may indicate response to therapy or
progression of HIV infection. OBJECTIVE: To evaluate the course of
CD8+CD38+ lymphocyte subset during continuous AZT-ddC combination
therapy as a possible predictive marker for response to antiretroviral
AZT-ddC combination therapy or progression of HIV disease. METHODS: In
an ongoing study CD8+CD38+ lymphocyte subsets of 25 HIV infected
individuals on AZT-ddC combination therapy were measured in two color
flow cytometry (Becton Dickinson FACScan and IMK Plus reagent kit).
Measurements were carried out monthly starting six months before
beginning the therapy. Patients on therapy were classified as responders
or non-responders according to further immunological and clinical
parameters and analysed separately. RESULTS: In about 200 tests in 25
HIV patients there was no clear evidence for course of CD8+CD38+
lymphocytes to indicate response to AZT-ddC combination therapy or
progression of HIV infection. DISCUSSION AND CONCLUSION: Objective and
practicable routine parameters for response to AZT-ddC combination
therapy are not satisfactory. Reports about the course of CD8+CD38+
lymphocyte subsets during this treatment have been scarse. According to
our results on a small group of patients the CD8+CD38+ lymphocyte subset
does not seem to be an additional or supplementary predictive marker for
response to AZT-ddC combination therapy. Further studies on more
individuals has to be carried out to widen results. Pre-treatment and
stage of HIVdisease would be interesting points of views to be taken
into consideration.
DE Antigens, CD8/*BLOOD Antigens, Differentiation/*BLOOD Drug Therapy,
Combination Flow Cytometry Follow-Up Studies Human HIV
Infections/*DRUG THERAPY/IMMUNOLOGY Leukocyte Count T-Lymphocyte
Subsets/*DRUG EFFECTS/IMMUNOLOGY Zalcitabine/*ADMINISTRATION & DOSAGE
Zidovudine/*ADMINISTRATION & DOSAGE MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).